• ScreenPro (SCRN) completes over 30,000 Covid-19 tests in March
  • The test used by Screenpro is the 1Drop PCR test kits, supplied by Datametrex AI Limited (TSXV: DM)
  • These tests can determine the new variants
  • ScreenPro provides turnkey coronavirus screening solutions to the private sector including testing, track and tracing with GoStop alerting software
  • ScreenPro Security Inc. (SCRN) is down 11.11 per cent and is trading at C$0.080 at 2:21 pm ET

ScreenPro Security Inc. (SCRN) continues to execute on its main business, Covid-19 testing for the film and television industry in Canada.

We are proud to share that the unaudited number of tests processed by the ScreenPro team for the month of March was over 30,000.

On March 16, 2021, ScreenPro announced it had processed approximately 60,000 tests in the months of January and February 2021.

The test used by Screenpro is the 1Drop PCR test kits, supplied by Datametrex AI Limited (TSXV: DM).

ScreenPro is proud to confirm it is using “best of class” test kits to ensure the safety of its clients’ workplace.

The manufacturer has confirmed that these tests can determine the new variants which is key as we navigate the third wave and the variants that are spreading at a fast pace globally.

John McMullen CEO,

“I am proud to share this update. Fiscal year-to-date, the company has processed approximately 90,000 tests.”

“We continue to add infrastructure to accommodate our clients needs, such as the launch of our first clinic in Vancouver, the new Rapid Antigen tests and GoStop app, which are key to driving new business. The Board of Directors have decided to report these testing results on a quarterly going forward,” added McMullen.

ScreenPro provides turnkey coronavirus screening solutions to the private sector including testing, track and tracing with GoStop alerting software.

ScreenPro Security Inc. (SCRN) is down 11.11 per cent and is trading at C$0.080 at 2:21 pm ET.

More From The Market Online

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.
The Market Online Video

Emerging opportunity in a growing, high-value dermatological market

Kane Biotech (TSXV:KNE) engages in the development and commercialization of products that prevent and remove microbial biofilms.